MX2018001040A - Moleculas de acido nucleico artificiales. - Google Patents
Moleculas de acido nucleico artificiales.Info
- Publication number
- MX2018001040A MX2018001040A MX2018001040A MX2018001040A MX2018001040A MX 2018001040 A MX2018001040 A MX 2018001040A MX 2018001040 A MX2018001040 A MX 2018001040A MX 2018001040 A MX2018001040 A MX 2018001040A MX 2018001040 A MX2018001040 A MX 2018001040A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- artificial nucleic
- utr
- utr element
- acid molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere a una molécula de ácido nucleico artificial que comprende al menos un marco de lectura abierto y al menos un elemento de región 3´ no traducida (elemento 3´-UTR) y/o al menos un elemento de región 5´ no traducida (elemento 5´-UTR), en donde la molécula de ácido nucleico artificial se caracteriza por eficiencia de traducción alta. La eficiencia de traducción es contribuida, al menos en parte, por el elemento 5´-UTR o el elemento 3´-UTR, o tanto el elemento 5´-UTR como el elemento 3´-UTR. La invención se refiere además al uso de esta molécula de ácido nucleico artificial en la terapia génica y/o vacunación genética. Además, se proporcionan elementos 3´-UTRs y elementos 5´-UTRs novedosos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015001755 | 2015-08-28 | ||
| PCT/EP2016/001417 WO2017036580A1 (en) | 2015-08-28 | 2016-08-22 | Artificial nucleic acid molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001040A true MX2018001040A (es) | 2018-06-15 |
Family
ID=54064264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001040A MX2018001040A (es) | 2015-08-28 | 2016-08-22 | Moleculas de acido nucleico artificiales. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180237786A1 (es) |
| EP (2) | EP3341482B1 (es) |
| JP (2) | JP7304155B2 (es) |
| KR (1) | KR102645398B1 (es) |
| CN (2) | CN108026537B (es) |
| AU (1) | AU2016316439B2 (es) |
| BR (1) | BR112018001995A2 (es) |
| CA (1) | CA2992801A1 (es) |
| DK (1) | DK3341482T3 (es) |
| ES (1) | ES2924739T3 (es) |
| MX (1) | MX2018001040A (es) |
| SG (1) | SG10201913629VA (es) |
| WO (1) | WO2017036580A1 (es) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| JP6456305B2 (ja) | 2013-02-22 | 2019-01-23 | キュアバック アーゲー | ワクチン接種とｐｄ−１経路の阻害との組み合わせ |
| RU2712743C2 (ru) | 2013-08-21 | 2020-01-30 | Куревак Аг | Вакцина против бешенства |
| SG10201801431TA (en) | 2013-08-21 | 2018-04-27 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
| LT3766916T (lt) | 2014-06-25 | 2023-01-10 | Acuitas Therapeutics Inc. | Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui |
| DE202015009974U1 (de) | 2014-12-12 | 2022-02-17 | Curevac Ag | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
| WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
| WO2016165831A1 (en) | 2015-04-17 | 2016-10-20 | Curevac Ag | Lyophilization of rna |
| US11384375B2 (en) | 2015-04-30 | 2022-07-12 | Curevac Ag | Immobilized poly(n)polymerase |
| DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
| AU2016264027A1 (en) | 2015-05-15 | 2017-08-31 | Curevac Ag | Prime-boost regimens involving administration of at least one mRNA construct |
| EP3928800A3 (en) | 2015-05-20 | 2022-03-23 | CureVac AG | Dry powder composition comprising long-chain rna |
| SG11201708540VA (en) | 2015-05-20 | 2017-12-28 | Curevac Ag | Dry powder composition comprising long-chain rna |
| WO2016193206A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
| EP3303575B1 (en) | 2015-05-29 | 2022-03-16 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| CN114085198A (zh) | 2015-06-29 | 2022-02-25 | 爱康泰生治疗公司 | 用于递送核酸的脂质和脂质纳米颗粒制剂 |
| WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
| EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| LT3368507T (lt) | 2015-10-28 | 2023-03-10 | Acuitas Therapeutics Inc. | Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui |
| WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
| DK3319622T3 (da) | 2015-12-22 | 2020-05-04 | Curevac Ag | Fremgangsmåde til fremstilling af rna-molekylesammensætninger |
| US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| SG11201806340YA (en) | 2016-02-17 | 2018-09-27 | Curevac Ag | Zika virus vaccine |
| US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
| WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| WO2017191264A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| BR112018075479A2 (pt) | 2016-06-09 | 2019-03-19 | Curevac Ag | portadores híbridos para carga de ácido nucleico |
| CA3025812A1 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
| US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
| JP2020501545A (ja) | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのｒｎａ |
| WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| US11524066B2 (en) | 2016-12-23 | 2022-12-13 | CureVac SE | Henipavirus vaccine |
| JP2020514370A (ja) | 2017-03-17 | 2020-05-21 | キュアバック アーゲー | 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤 |
| KR20190133699A (ko) * | 2017-03-24 | 2019-12-03 | 큐어백 아게 | Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도 |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| EP3618859A4 (en) | 2017-04-27 | 2021-05-05 | Vanderbilt University | HEPATITIS C VIRUS SEQUENCES AND METHODS OF USING THEREFORE |
| EP4410317A3 (en) | 2017-04-28 | 2024-10-30 | Acuitas Therapeutics Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2019036008A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| CA3073018A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
| CA3073634A1 (en) * | 2017-10-19 | 2019-04-25 | Curevac Ag | Novel artificial nucleic acid molecules |
| EP3707271A1 (en) | 2017-11-08 | 2020-09-16 | CureVac AG | Rna sequence adaptation |
| WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
| SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
| US20210361761A1 (en) | 2018-04-05 | 2021-11-25 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| WO2019202035A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| AU2019410737A1 (en) | 2018-12-21 | 2021-06-10 | CureVac SE | RNA for malaria vaccines |
| CA3125511A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| MX2022001870A (es) | 2019-08-14 | 2022-05-30 | Curevac Ag | Combinaciones y composiciones de arn con propiedades inmunoestimuladoras disminuidas. |
| CN110812366B (zh) * | 2019-11-18 | 2023-11-17 | 珠海丽凡达生物技术有限公司 | 一种可用于激素补充的mRNA药物及其制备方法 |
| BR112022014627A2 (pt) | 2020-02-04 | 2022-09-27 | Curevac Ag | Vacina contra coronavírus |
| US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| CN111494631B (zh) * | 2020-04-27 | 2022-10-18 | 北京大学人民医院 | 一种原发性免疫性血小板减少症miRNA标记物及其应用 |
| IL298084A (en) | 2020-05-29 | 2023-01-01 | CureVac SE | Nucleic acid-based combination vaccines |
| CN116096702A (zh) | 2020-07-16 | 2023-05-09 | 爱康泰生治疗公司 | 用于脂质纳米颗粒的阳离子脂质 |
| CA3170741A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| US20240066114A1 (en) | 2020-08-31 | 2024-02-29 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| CA3205569A1 (en) | 2020-12-22 | 2022-06-30 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| EP4087938A2 (en) | 2021-01-27 | 2022-11-16 | CureVac AG | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| US20240181037A1 (en) | 2021-03-26 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
| EP4334446A1 (en) | 2021-05-03 | 2024-03-13 | CureVac SE | Improved nucleic acid sequence for cell type specific expression |
| AU2022284878A1 (en) | 2021-06-04 | 2024-01-18 | Translate Bio, Inc. | Assay for quantitative assessment of mrna capping efficiency |
| US20240301433A1 (en) * | 2021-06-24 | 2024-09-12 | Hanmi Pharm. Co., Ltd. | Non-natural 5'-untranslated region and 3'-untranslated region and use thereof |
| WO2023008793A1 (ko) * | 2021-07-27 | 2023-02-02 | 에스케이바이오사이언스(주) | 단백질 발현을 위한 mrna와 이를 위한 주형 |
| CN117999355A (zh) | 2021-08-24 | 2024-05-07 | 生物技术欧洲股份公司 | 体外转录技术 |
| CN118647600A (zh) | 2021-12-16 | 2024-09-13 | 爱康泰生治疗公司 | 用于脂质纳米颗粒制剂的脂质 |
| CN115404238A (zh) * | 2021-12-22 | 2022-11-29 | 江苏拓弘康恒医药有限公司 | 高翻译稳定性BDNF mRNA的设计和制备方法 |
| WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN114540307A (zh) * | 2022-02-16 | 2022-05-27 | 多莱泌生物科技(武汉)有限公司 | 一种靶向肝脏的工程化外泌体制备方法 |
| AU2023274371A1 (en) | 2022-05-25 | 2024-10-31 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
| WO2024098361A1 (zh) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
| WO2024098360A1 (zh) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| CN117487809B (zh) * | 2023-12-29 | 2024-03-19 | 艾斯拓康医药科技(北京)有限公司 | 一种优化的5`utr序列及其应用 |
| CN117535295B (zh) * | 2024-01-09 | 2024-04-26 | 艾斯拓康医药科技(北京)有限公司 | 一种优化的3`utr序列及其应用 |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| ES2240745T3 (es) | 2001-06-05 | 2005-10-16 | Curevac Gmbh | Composicion farmaceutica que contiene un arnm estabilizado y optimizado para la traduccion, adecuada como vacuna y como regenerante de tejidos. |
| EP2135080A4 (en) * | 2007-03-08 | 2010-12-01 | Switchgear Genomics | FUNCTIONAL ARRAYS FOR CHARACTERIZATION WITH HIGH PASSAGE OF REGULATORY ELEMENTS IN NONTRANSLATED SURFACES OF GENES |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CN103025876A (zh) | 2010-07-30 | 2013-04-03 | 库瑞瓦格有限责任公司 | 用于转染和免疫刺激的核酸与二硫化物交联的阳离子成分的复合体 |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| CN108929880A (zh) | 2012-03-27 | 2018-12-04 | 库瑞瓦格股份公司 | 包含5′toputr的人工核酸分子 |
| RU2658490C2 (ru) * | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| SG11201405542UA (en) * | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
| US8999380B2 (en) * | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| SG10201801428RA (en) * | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
| MX2016008551A (es) | 2013-12-30 | 2016-09-26 | Curevac Ag | Moleculas artificiales de acido nucleico. |
| WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
| AU2015373404B2 (en) | 2014-12-30 | 2021-09-09 | CureVac SE | Artificial nucleic acid molecules |
-
2016
- 2016-08-22 AU AU2016316439A patent/AU2016316439B2/en active Active
- 2016-08-22 KR KR1020187008732A patent/KR102645398B1/ko active IP Right Grant
- 2016-08-22 CN CN201680049973.1A patent/CN108026537B/zh active Active
- 2016-08-22 EP EP16759979.4A patent/EP3341482B1/en active Active
- 2016-08-22 US US15/755,739 patent/US20180237786A1/en active Pending
- 2016-08-22 DK DK16759979.4T patent/DK3341482T3/da active
- 2016-08-22 MX MX2018001040A patent/MX2018001040A/es unknown
- 2016-08-22 CA CA2992801A patent/CA2992801A1/en active Pending
- 2016-08-22 BR BR112018001995A patent/BR112018001995A2/pt active Search and Examination
- 2016-08-22 SG SG10201913629VA patent/SG10201913629VA/en unknown
- 2016-08-22 CN CN202210036661.4A patent/CN114381470A/zh active Pending
- 2016-08-22 JP JP2018511127A patent/JP7304155B2/ja active Active
- 2016-08-22 EP EP22176444.2A patent/EP4108774A1/en active Pending
- 2016-08-22 ES ES16759979T patent/ES2924739T3/es active Active
- 2016-08-22 WO PCT/EP2016/001417 patent/WO2017036580A1/en active Application Filing
-
2021
- 2021-08-16 JP JP2021132110A patent/JP7245878B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108026537A (zh) | 2018-05-11 |
| KR20180038564A (ko) | 2018-04-16 |
| EP3341482A1 (en) | 2018-07-04 |
| BR112018001995A2 (pt) | 2018-09-18 |
| SG10201913629VA (en) | 2020-03-30 |
| RU2018110872A (ru) | 2019-10-01 |
| WO2017036580A1 (en) | 2017-03-09 |
| AU2016316439B2 (en) | 2022-02-24 |
| DK3341482T3 (da) | 2022-08-15 |
| JP2018529329A (ja) | 2018-10-11 |
| AU2016316439A1 (en) | 2018-02-08 |
| CN114381470A (zh) | 2022-04-22 |
| EP4108774A1 (en) | 2022-12-28 |
| RU2018110872A3 (es) | 2020-07-24 |
| US20180237786A1 (en) | 2018-08-23 |
| EP3341482B1 (en) | 2022-07-06 |
| JP2021192613A (ja) | 2021-12-23 |
| ES2924739T3 (es) | 2022-10-10 |
| CN108026537B (zh) | 2022-02-08 |
| JP7245878B2 (ja) | 2023-03-24 |
| KR102645398B1 (ko) | 2024-03-07 |
| CA2992801A1 (en) | 2017-03-09 |
| JP7304155B2 (ja) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001040A (es) | Moleculas de acido nucleico artificiales. | |
| MX2020003245A (es) | Moleculas artificiales de acido nucleico. | |
| MX2017008670A (es) | Moleculas artificiales de acido nucleico novedosas. | |
| MX357803B (es) | Moléculas de ácido nucleico artificiales. | |
| EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
| MX358706B (es) | Moleculas de acido nucleico artificiales que comprenden un top 5´utr. | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| MX362981B (es) | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. | |
| WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
| IL280652A (en) | Nucleic acid molecules and their use for non-viral gene therapy | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| MX2018011384A (es) | Arn de replicacion en trans. | |
| BR112019001887A2 (pt) | composições e métodos para o tratamento de doença associada a cep290 | |
| MX2016009771A (es) | Metodos y productos para la produccion y administracion de acido nucleico. | |
| EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
| MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
| SA519401379B1 (ar) | علاج فيروس مرتبط بغدة لمرض هنتنجتون | |
| MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
| MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
| CA3057899A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
| MX2021004391A (es) | Proteinas inteinas y usos de las mismas. | |
| NZ752941A (en) | Frataxin expression constructs | |
| EA201691981A1 (ru) | Улучшенные транспортные молекулы модулярного антигена и их применение |